Incidence and impact of new-onset atrial fibrillation on transcatheter mitral valve repair

Published: 26 September 2018
Author(s): Rajkumar Doshi, Krunalkumar Patel, Rupak Desai, Keyur Patel, Rajeev Gupta
Section: Letter to the Editor

Transcatheter mitral valve repair (TMVr) has been approved, in the United States, for the treatment of degenerative mitral valve regurgitation (MR) in certain high surgical risk or inoperable patients. In a recent study by Jabs et al., the in-hospital outcomes (at 12 months) of pre-existing atrial fibrillation (Afib) did not differ considerably from those with sinus rhythm in regard to either major adverse cardiac and cerebrovascular event (MACCE) rates or clinical improvements [1]. However, it should be noted that Afib is a frequently encountered adverse outcome in the TMVr procedure [1] and is, in general, a marker for advanced heart failure [2].